# Caribou Biosciences, Inc.: financial statements, quarterly

CRBU · Nasdaq · CIK 1619856 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crbu.md) · [Financials](/companies/crbu/financials.md) · [Filings](/companies/crbu/filings.md) · [Insiders](/companies/crbu/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crbu/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [23.7](/filings/0001619856-24-000081.md) | [3.6 d](/filings/0001619856-25-000015.md) | [2.4](/filings/0001619856-25-000043.md) | [3.5](/filings/0001619856-25-000061.md) | [2.0](/filings/0001619856-25-000071.md) | [2.1 d](/filings/0001619856-26-000008.md) | [2.4](/filings/0001619856-26-000036.md) | [2.7](/filings/0001619856-26-000055.md) | [2.2](/filings/0001619856-25-000071.md) | [3.9 d](/filings/0001619856-26-000008.md) | [2.4](/filings/0001619856-26-000036.md) | [1.5](/filings/0001619856-26-000055.md) |
| Research and development | $m | [28.6](/filings/0001619856-24-000081.md) | [31.3 d](/filings/0001619856-25-000015.md) | [33.8](/filings/0001619856-25-000043.md) | [35.5](/filings/0001619856-25-000061.md) | [30.4](/filings/0001619856-25-000071.md) | [30.5 d](/filings/0001619856-26-000008.md) | [35.5](/filings/0001619856-26-000036.md) | [27.7](/filings/0001619856-26-000055.md) | [22.4](/filings/0001619856-25-000071.md) | [23.8 d](/filings/0001619856-26-000008.md) | [20.6](/filings/0001619856-26-000036.md) | [18.9](/filings/0001619856-26-000055.md) |
| Operating income | $m | [(14.6)](/filings/0001619856-24-000081.md) | [(37.4) d](/filings/0001619856-25-000015.md) | [(46.0)](/filings/0001619856-25-000043.md) | [(43.5)](/filings/0001619856-25-000061.md) | [(38.2)](/filings/0001619856-25-000071.md) | [(38.9) d](/filings/0001619856-26-000008.md) | [(42.9)](/filings/0001619856-26-000036.md) | [(47.6)](/filings/0001619856-26-000055.md) | [(29.4)](/filings/0001619856-25-000071.md) | [(28.5) d](/filings/0001619856-26-000008.md) | [(26.3)](/filings/0001619856-26-000036.md) | [(25.3)](/filings/0001619856-26-000055.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001619856-24-000081.md) | [0.2 d](/filings/0001619856-25-000015.md) | [0.0](/filings/0001619856-25-000043.md) | [0.0](/filings/0001619856-24-000064.md) | [0.0](/filings/0001619856-24-000081.md) | [(0.0) d](/filings/0001619856-26-000008.md) | [0.0](/filings/0001619856-25-000043.md) | not reported | [0.0](/filings/0001619856-25-000071.md) | [(0.6) d](/filings/0001619856-26-000008.md) | [0.0](/filings/0001619856-26-000036.md) | not reported |
| Net income | $m | [(10.0)](/filings/0001619856-24-000081.md) | [(34.5) d](/filings/0001619856-25-000015.md) | [(41.2)](/filings/0001619856-25-000071.md) | [(37.7)](/filings/0001619856-25-000071.md) | [(34.7)](/filings/0001619856-25-000071.md) | [(35.5) d](/filings/0001619856-26-000008.md) | [(40.0)](/filings/0001619856-26-000055.md) | [(54.1)](/filings/0001619856-26-000055.md) | [(27.5)](/filings/0001619856-25-000071.md) | [(26.5) d](/filings/0001619856-26-000008.md) | [(25.1)](/filings/0001619856-26-000055.md) | [(24.3)](/filings/0001619856-26-000055.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001619856-24-000081.md) | not reported | [(0.46)](/filings/0001619856-25-000043.md) | [(0.42)](/filings/0001619856-25-000061.md) | [(0.38)](/filings/0001619856-25-000071.md) | not reported | [(0.43)](/filings/0001619856-26-000036.md) | [(0.58)](/filings/0001619856-26-000055.md) | [(0.30)](/filings/0001619856-25-000071.md) | not reported | [(0.26)](/filings/0001619856-26-000036.md) | [(0.24)](/filings/0001619856-26-000055.md) |
| Basic EPS | $ per share | [(0.12)](/filings/0001619856-24-000081.md) | not reported | [(0.46)](/filings/0001619856-25-000043.md) | [(0.42)](/filings/0001619856-25-000061.md) | [(0.38)](/filings/0001619856-25-000071.md) | not reported | [(0.43)](/filings/0001619856-26-000036.md) | [(0.58)](/filings/0001619856-26-000055.md) | [(0.30)](/filings/0001619856-25-000071.md) | not reported | [(0.26)](/filings/0001619856-26-000036.md) | [(0.24)](/filings/0001619856-26-000055.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [104](/filings/0001619856-24-000081.md) | [51.2](/filings/0001619856-25-000015.md) | [49.4](/filings/0001619856-25-000043.md) | [37.9](/filings/0001619856-25-000061.md) | [32.0](/filings/0001619856-25-000071.md) | [16.3](/filings/0001619856-26-000008.md) | [29.4](/filings/0001619856-26-000036.md) | [25.2](/filings/0001619856-26-000055.md) | [11.1](/filings/0001619856-25-000071.md) | [12.4](/filings/0001619856-26-000055.md) | [12.1](/filings/0001619856-26-000036.md) | [26.2](/filings/0001619856-26-000055.md) |
| Current assets | $m | [351](/filings/0001619856-23-000124.md) | [339](/filings/0001619856-25-000015.md) | [305](/filings/0001619856-24-000038.md) | [271](/filings/0001619856-24-000064.md) | [237](/filings/0001619856-24-000081.md) | [219](/filings/0001619856-26-000008.md) | [217](/filings/0001619856-25-000043.md) | [193](/filings/0001619856-25-000061.md) | [156](/filings/0001619856-25-000071.md) | [145](/filings/0001619856-26-000055.md) | [122](/filings/0001619856-26-000036.md) | [117](/filings/0001619856-26-000055.md) |
| Total assets | $m | [458](/filings/0001619856-23-000124.md) | [432](/filings/0001619856-25-000015.md) | [407](/filings/0001619856-24-000038.md) | [373](/filings/0001619856-24-000064.md) | [344](/filings/0001619856-24-000081.md) | [313](/filings/0001619856-26-000008.md) | [274](/filings/0001619856-25-000043.md) | [221](/filings/0001619856-25-000061.md) | [195](/filings/0001619856-25-000071.md) | [175](/filings/0001619856-26-000055.md) | [149](/filings/0001619856-26-000036.md) | [143](/filings/0001619856-26-000055.md) |
| Current liabilities | $m | [24.6](/filings/0001619856-23-000124.md) | [28.3](/filings/0001619856-25-000015.md) | [29.0](/filings/0001619856-24-000038.md) | [30.9](/filings/0001619856-24-000064.md) | [32.2](/filings/0001619856-24-000081.md) | [30.7](/filings/0001619856-26-000008.md) | [28.5](/filings/0001619856-25-000043.md) | [28.9](/filings/0001619856-25-000061.md) | [28.1](/filings/0001619856-25-000071.md) | [25.4](/filings/0001619856-26-000055.md) | [19.7](/filings/0001619856-26-000036.md) | [18.0](/filings/0001619856-26-000055.md) |
| Total liabilities | $m | [59.3](/filings/0001619856-23-000124.md) | [63.8](/filings/0001619856-25-000015.md) | [63.5](/filings/0001619856-24-000038.md) | [62.5](/filings/0001619856-24-000064.md) | [63.1](/filings/0001619856-24-000081.md) | [60.4](/filings/0001619856-26-000008.md) | [56.4](/filings/0001619856-25-000043.md) | [54.8](/filings/0001619856-25-000061.md) | [53.1](/filings/0001619856-25-000071.md) | [53.2](/filings/0001619856-26-000055.md) | [47.0](/filings/0001619856-26-000036.md) | [44.7](/filings/0001619856-26-000055.md) |
| Shareholders' equity | $m | [398](/filings/0001619856-24-000081.md) | [368](/filings/0001619856-26-000008.md) | [343](/filings/0001619856-25-000071.md) | [310](/filings/0001619856-25-000071.md) | [281](/filings/0001619856-25-000071.md) | [253](/filings/0001619856-26-000055.md) | [217](/filings/0001619856-26-000055.md) | [166](/filings/0001619856-26-000055.md) | [142](/filings/0001619856-25-000071.md) | [122](/filings/0001619856-26-000055.md) | [102](/filings/0001619856-26-000055.md) | [98.1](/filings/0001619856-26-000055.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(28.8) d](/filings/0001619856-24-000081.md) | [(21.4) d](/filings/0001619856-25-000015.md) | [(37.2)](/filings/0001619856-25-000043.md) | [(32.9) d](/filings/0001619856-25-000061.md) | [(32.7) d](/filings/0001619856-25-000071.md) | [(35.5) d](/filings/0001619856-26-000008.md) | [(36.7)](/filings/0001619856-26-000036.md) | [(28.3) d](/filings/0001619856-26-000055.md) | [(25.2) d](/filings/0001619856-25-000071.md) | [(20.8) d](/filings/0001619856-26-000008.md) | [(27.0)](/filings/0001619856-26-000036.md) | [(22.8) d](/filings/0001619856-26-000055.md) |
| Capital expenditure | $m | [4.8 d](/filings/0001619856-24-000081.md) | [2.3 d](/filings/0001619856-25-000015.md) | [1.4](/filings/0001619856-25-000043.md) | [2.2 d](/filings/0001619856-25-000061.md) | [0.7 d](/filings/0001619856-25-000071.md) | [0.5 d](/filings/0001619856-26-000008.md) | [1.0](/filings/0001619856-26-000036.md) | [0.4 d](/filings/0001619856-26-000055.md) | [0.1 d](/filings/0001619856-25-000071.md) | [(0.2) d](/filings/0001619856-26-000008.md) | [0.1](/filings/0001619856-26-000036.md) | [0.0 d](/filings/0001619856-26-000055.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [60.9](/filings/0001619856-23-000124.md) | [61.2](/filings/0001619856-24-000038.md) | [61.4](/filings/0001619856-24-000064.md) | [83.8](/filings/0001619856-24-000081.md) | [89.3](/filings/0001619856-25-000043.md) | [90.3](/filings/0001619856-25-000061.md) | [90.5](/filings/0001619856-25-000071.md) | [92.7](/filings/0001619856-26-000036.md) | [93.0](/filings/0001619856-26-000055.md) | [93.3](/filings/0001619856-25-000071.md) | [95.9](/filings/0001619856-26-000036.md) | [101](/filings/0001619856-26-000055.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 107,207,513 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001619856-26-000055.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.